PharmaTwoB was founded by a group of highly experienced professionals from the Israeli pharmaceutical industry, with strong track record in drug delivery, chemistry, finance and strategic planning. The company’s management and staff are highly skilled scientists with many years of experience in research and development of drugs, pharmaceutical development and clinical trials.
David S. Tierney, MD, CEO
An entrepreneurial pharmaceutical and med-tech executive with over 30 years experience, who has overseen the growth and successful exit of a number of specialty pharmaceutical and medical device companies. Most recently, Dr. Tierney served as President and CEO of BioPharmX. Prior to this, Dr. Tierney served as President and CEO of Icon Bioscience, overseeing the FDA approval of its New Drug Application (NDA) for DEXYCU™ in 2018. Dr. Tierney was President and COO of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. Prior to this David was CEO of Valera Pharmaceuticals, where he raised over $65 million in funding and completed a successful IPO and oversaw the NDA approvals of VANTAS™ and SUPPRELIN LA™. In addition to Dr. Tierney’s leadership roles, has held a position with investment firm, Signet Health Partners. He is the recipient of two Ernst & Young Entrepreneur of the Year® awards. Dr. Tierney serves on the board of directors of Catalyst Pharmaceuticals, Kempharm, and Bimeda. Dr. Tierney received his medical degree from The Royal College of Surgeons in Dublin, Ireland.
Irit Zalayet, CFO
Ms. Irit Zalayet CPA serves as Pharma Two B’s CFO as of September 2010. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar- Ilan University. Ms. Zalayet also serves as the CFO of a related group party Stem Cell Medicine.
Hadas Friedman, VP QA, RA & Clinical Affairs
Ms. Friedman serves as Pharma Two B’s VP QA, RA and Clinical Affairs since 2013. Prior to this Ms. Friedman served as the VP QA, RA and Clinical Affairs at Intec Pharma from 2004. Previous companies include Procognia and Rafa Laboratories. Hadas has completed a Bachelors of Science and a Masters of Science at the Bar-Ilan University.